Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a study titled ‘A Prospective Non-Interventional Study to Describe the Effectiveness and Safety of Venetoclax as a First-Line Treatment in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible to Intensive Chemotherapy in Routine Clinical Practice in Greece.’ The study aims to evaluate the effectiveness and safety of Venetoclax, a drug approved for treating AML, in patients who cannot undergo intensive chemotherapy. This study is significant as it focuses on a common form of acute leukemia in adults, potentially offering a viable treatment option for those ineligible for more aggressive therapies.
The intervention being tested is Venetoclax, an oral medication designed to treat Acute Myeloid Leukemia. Participants will receive Venetoclax tablets daily, following the approved local label, with the goal of assessing the drug’s effectiveness and safety in routine clinical practice.
This observational study follows a cohort model with a prospective time perspective. It involves approximately 100 participants across 15 sites in Greece, with no additional burden on participants as all visits align with routine clinical practice. The study’s primary purpose is to gather real-world data on Venetoclax’s performance in treating AML.
The study began on May 26, 2022, with an estimated completion timeline of 30 months. The most recent update was submitted on July 15, 2025, indicating ongoing recruitment and data collection. These dates are crucial for tracking the study’s progress and ensuring timely analysis of results.
The market implications of this study could be significant for AbbVie, as positive outcomes may enhance investor confidence and potentially influence stock performance. In the competitive landscape of AML treatments, demonstrating Venetoclax’s effectiveness could strengthen AbbVie’s position and offer a competitive edge.
The study is currently recruiting, with further details available on the ClinicalTrials portal.